EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSBTAG00000021461
Gene Symbol: PSMD3
120 Enzyme and pathways 5 Cross references
106 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSBTAG00000015112
Gene Symbol: PSMD6
120 Enzyme and pathways 5 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSBTAG00000018425
Gene Symbol: PSMD7
120 Enzyme and pathways 5 Cross references
254 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSBTAG00000031641
Gene Symbol: PSMD8
119 Enzyme and pathways 5 Cross references
225 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSBTAG00000054080
Gene Symbol: PSMB11
105 Enzyme and pathways 3 Cross references
240 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSBTAG00000010890
Gene Symbol: PRMT5
12 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSBTAG00000001061
Gene Symbol: PRKCA
5 Cross references
225 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSBTAG00000020921
Gene Symbol: PRKCB
34 Enzyme and pathways 5 Cross references
312 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSBTAG00000008719
Gene Symbol: PRKCD
41 Enzyme and pathways 5 Cross references
295 Possible Orthologues:

Protein Kinase C Epsilon

Ensembl ID : ENSBTAG00000020614
Gene Symbol: PRKCE
5 Cross references
321 Possible Orthologues:

Protein Kinase C Eta

Ensembl ID : ENSBTAG00000003276
Gene Symbol: PRKCH
7 Enzyme and pathways 5 Cross references
253 Possible Orthologues:

Protein Kinase C Gamma

Ensembl ID : ENSBTAG00000013550
Gene Symbol: PRKCG
5 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).